You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥(01093.HK)附屬授予Corbus治療癌症藥物歐美等地獨家開發權
阿思達克 02-13 08:45
石藥集團(01093.HK)公布,其附屬石藥巨石生物已與Corbus Pharmaceuticals就集團重組人源化抗Nectin-4抗體藥物偶聯物SYS6002,在美國、歐盟國家、英國、加拿大、澳洲、冰島、列支敦士登、挪威及瑞士的開發及商業化訂立獨家授權協議。 據此,石藥巨石生物同意授予Corbus Pharmaceuticals在該地區開發及商業化該產品的獨家授權。石藥巨石生物將收取750萬美元的首付款,並有權收取最多1.3億美元的潛在開發及監管里程碑付款以及最多5.55億美元的潛在銷售里程碑付款。 公司指出,通過採用集團專有的(酉每)催化定點抗體偶聯技術,SYS6002能將有效的有絲分裂抑制劑MMAE針對性地導向Nectin-4表達的癌細胞,而其連接子的穩定性有助於將高濃度的MMAE送達腫瘤中,並同時通過減少不良的全身暴露量而將副作用減低。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account